A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab

Inclusion Criteria:

1. Patients with histologically confirmed glioblastoma or other grade IV malignant
glioma (i.e. gliosarcoma, small cell glioblastoma, etc.), recurrent after prior
external-beam fractionated radiotherapy and temozolomide chemotherapy.

2. Patients with documented radiographic progression following bevacizumab therapy for
treatment of glioblastoma or other grade IV malignant glioma (the patient must be on
bevacizumab at the time of last progression).

3. Patients with up to 2 prior recurrences are allowed.

4. Karnofsky performance status ≥ 60%.

5. Age ≥ 18 years old.

6. Normal organ function

Exclusion Criteria:

- Patients who have had previous treatment with TRC105.

- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to
starting study drug, or patients who have had minor procedures, percutaneous biopsies
or placement of vascular access device ≤ 1 week prior to starting study drug, or who
have not recovered from side effects of such procedure or injury

- Patients with cirrhosis, or active viral or nonviral hepatitis.

- Patients with active bleeding or pathologic conditions that carry a high risk of
bleeding,(i.e. hereditary hemorrhagic telangiectasia).

- Patients who are currently receiving anticoagulation treatment

- Patients unwilling or unable to comply with the protocol